Edward Tatum and the Wartime Development of Bacterial Genetics?

Edward Lawrie Tatum (1909–1975) was an American biochemist whose wartime research on genetic mutation in bacteria provided the molecular foundation for twentieth-century medicine in the absence of systemic chemical antimicrobials. His work, conducted largely between 1941 and 1945 at Stanford University, demonstrated that bacterial traits—including those that conferred resistance to infection or increased virulence—could be inherited, selected for, and predicted to evolve. In a world where the azo drugs remained the only systemic antibacterial agents available, Tatum's discoveries reshaped how physicians and epidemiologists understood the limits of chemical treatment and the inevitability of asepsis-based defense.

Tatum began his career in the 1930s studying biochemical pathways in fungi at the University of Wisconsin and Stanford. His early work involved exposing organisms to X-rays and chemical mutagens to induce visible changes in growth or pigmentation. In 1941, working with Joshua Lederberg, a Stanford graduate student eight years his junior, Tatum began systematically breeding and crossing strains of bacteria in order to understand how heritable variation arose and spread. Their method was simple: they exposed bacteria to radiation, selected for survivors showing new traits, then crossed the mutated strains to determine whether the traits bred true across generations. By 1943, they had published their first results demonstrating bacterial recombination—the exchange of genetic material between cells.

The significance of this work lay not in the immediate results but in their implication. The United States military had begun encountering battlefield sepsis at rates far higher than expected. The 1943 invasion of Sicily, in particular, saw casualty evacuation rates climbing steeply as wound infections that might have responded to sulfonamides in the laboratory progressed to septicaemia and gangrene in the field. Army medical officers, studying the failure of azo drugs in real patients, began asking why: were the bacteria becoming resistant? Was it the heat, the duration of therapy, the dosage? Tatum's work suggested an answer that the military and the medical establishment found both troubling and clarifying. If bacterial traits were heritable, then resistance to the azo drugs could be selected for naturally under the pressure of ongoing chemical exposure. The very treatment being applied might be selecting for more resistant populations.

This insight—which Tatum himself did not initially frame in military terms—circulated rapidly through military medical research during 1943 and 1944. The Armed Forces Medical Library distributed reprints of Tatum and Lederberg's papers to field hospitals. Medical journals reprinted discussions of their work alongside casualty statistics. By 1944, the implication had become clear to military planners: systemic chemical therapy might never fully eliminate bacterial infection if the organisms under treatment could adapt more quickly than new drugs could be synthesized. This reasoning did not end the development of new azo drugs—Bayer and other manufacturers continued synthesizing variants throughout the war and after—but it fundamentally altered strategic assumptions about what medicine could accomplish. If bacteria could evolve resistance, then prevention through isolation, sterilization, and asepsis became not merely a supplement to chemical treatment but potentially its only reliable foundation.

Tatum continued his work after the war at Stanford and later at the University of Wisconsin, where he and Lederberg's wider research program attracted a generation of postwar bacteriologists and geneticists. He did not write extensively about infection control or medical policy; his publications focused on the molecular mechanisms of mutation and heredity. Yet his work had already entered clinical consensus. By the time the Bacillary Congress of Geneva convened in 1952 to formalize asepsis maximalism as the coordinated international response to untreatable infection, Tatum's research was cited repeatedly as the scientific justification: if bacteria evolved, asepsis was not a choice but an necessity.

Tatum shared the 1958 Nobel Prize in Physiology or Medicine with Lederberg and George Beadle for work on genetic regulation in microorganisms. His later years saw him appointed director of the Division of Genetics at the Rockefeller Institute, where he continued studying the genetic basis of bacterial metabolism until his death in 1975. By then, serum therapy had begun to emerge as a clinical alternative to the azo drugs, but it was Tatum's earlier work on the limits of chemical treatment that had prepared medicine to accept—even to expect—the absence of a chemical cure.